

Satoshi Morita

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4475828/publications.pdf>

Version: 2024-02-01

166
papers

12,012
citations

201674

27
h-index

26613

107
g-index

170
all docs

170
docs citations

170
times ranked

10896
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2022, 10, 72-82. | 10.7 | 62 |
| 2 | Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study. <i>Gastric Cancer</i> , 2022, 25, 207-217. | 5.3 | 9 |
| 3 | Differences between subjective and objective sleep duration according to actual sleep duration and sleep-disordered breathing: the Nagahama Study. <i>Journal of Clinical Sleep Medicine</i> , 2022, 18, 851-859. | 2.6 | 7 |
| 4 | Exploratory analysis of baseline tumor burden in the TRUSTY study: A randomized phase 2/3 study of trifluridine/tipiracil plus bevacizumab versus irinotecan and fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 87-87. | 1.6 | 1 |
| 5 | Clinical results of dynamic tumor-tracking stereotactic body radiotherapy with real-time monitoring for liver tumors using a gimbal-mounted linac: A multi-institutional phase II study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 441-441. | 1.6 | 1 |
| 6 | Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative postmenopausal breast cancer: an <i>ad hoc</i> analysis of the JBCRG-C06 Safari study. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 545-553. | 1.3 | 4 |
| 7 | A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT study. <i>Langenbeck's Archives of Surgery</i> , 2022, 407, 1345-1356. | 1.9 | 3 |
| 8 | Prospective observational study of the efficacy of oral uracil and tegafur plus leucovorin for stage II colon cancer with risk factors for recurrence using propensity score matching (JFMC46-1201). <i>BMC Cancer</i> , 2022, 22, 170. | 2.6 | 5 |
| 9 | Evaluation of respiratory rate monitoring performance using a home oxygen monitoring device among patients with interstitial lung disease and chronic obstructive pulmonary disease.. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2022, 39, e2022007. | 0.2 | 0 |
| 10 | Randomized controlled trial of the significance of combined use with Ninjinâ€™yoeito in CapeOX + Bmab therapy for patients with unresectable advanced/recurrent colorectal cancer. <i>Medicine, Case Reports and Study Protocols</i> , 2022, 3, e0196. | 0.1 | 0 |
| 11 | Afatinib (AFA) plus bevacizumab (BEV) combination after osimertinib (OSI) resistance in advanced EGFR-mutant NSCLC: A phase II study (ABCD-study).. <i>Journal of Clinical Oncology</i> , 2022, 40, 9117-9117. | 1.6 | 0 |
| 12 | A phase II study of osimertinib in combination with platinum plus pemetrexed in patients with EGFR-mutated, advanced nonâ€™small cell lung cancer: The OPAL study (NEJ032C/LOGIK1801).. <i>Journal of Clinical Oncology</i> , 2022, 40, 9097-9097. | 1.6 | 1 |
| 13 | A semiparametric Bayesian approach to population finding with timeâ€™toâ€™event and toxicity data in a randomized clinical trial. <i>Biometrics</i> , 2021, 77, 634-648. | 1.4 | 1 |
| 14 | Are volume-dependent parameters in positron emission tomography predictive of postoperative recurrence after resection in patients with thymic carcinoma?. <i>Surgery Today</i> , 2021, 51, 322-326. | 1.5 | 3 |
| 15 | Employing multiple-attribute utility technology to evaluate publicity activities for cancer information and counseling programs in Japan. <i>Journal of Cancer Policy</i> , 2021, 27, 100261. | 1.4 | 0 |
| 16 | Prognostic significance of natriuretic peptide levels in atrial fibrillation without heart failure. <i>Heart</i> , 2021, 107, 705-712. | 2.9 | 16 |
| 17 | Impact of sleep-disordered breathing on glucose metabolism among individuals with a family history of diabetes: the Nagahama study. <i>Journal of Clinical Sleep Medicine</i> , 2021, 17, 129-140. | 2.6 | 1 |
| 18 | Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatinâ€™based or irinotecanâ€™based therapy for colorectal cancer. <i>Cancer Science</i> , 2021, 112, 1567-1578. | 3.9 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Estimating Similarity of Dose-Response Relationships in Phase I Clinical Trials Case Study in Bridging Data Package. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 1639. | 2.6 | 3 |
| 20 | Proton Pump Inhibitor Use and the Efficacy of Chemotherapy in Metastatic Colorectal Cancer: A Post Hoc Analysis of a Randomized Phase III Trial (AXEPT). <i>Oncologist</i> , 2021, 26, e954-e962. | 3.7 | 14 |
| 21 | Proposal of a novel H category-based classification of colorectal liver metastases based on a Japanese nationwide survey. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2021, 28, 317-326. | 2.6 | 10 |
| 22 | Multiparametric magnetic resonance imaging facilitates the selection of patients prior to fertility-sparing management of endometrial cancer. <i>Abdominal Radiology</i> , 2021, 46, 4410-4419. | 2.1 | 4 |
| 23 | Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19). <i>International Journal of Clinical Oncology</i> , 2021, 26, 1229-1236. | 2.2 | 3 |
| 24 | Markers of cardiovascular disease risk in sleep-disordered breathing with or without comorbidities: the Nagahama Study. <i>Journal of Clinical Sleep Medicine</i> , 2021, 17, 2467-2475. | 2.6 | 1 |
| 25 | The 2020 Edition of the Clinical Guidelines for Lung Cancer: Challenges and Future Perspectives. <i>Japanese Journal of Lung Cancer</i> , 2021, 61, 163-170. | 0.1 | 0 |
| 26 | Lymph node dissection in thymic carcinomas and neuroendocrine carcinomas. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2021, 33, 242-249. | 1.1 | 3 |
| 27 | Impact of <i>UGT1A1</i> genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer. <i>Cancer Science</i> , 2021, 112, 4669-4678. | 3.9 | 8 |
| 28 | Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial. <i>European Journal of Cancer</i> , 2021, 154, 296-306. | 2.8 | 5 |
| 29 | Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1523-1532. | 1.1 | 57 |
| 30 | Effects of Goshajinkigan (TJ-107) for oxaliplatin-induced peripheral neurotoxicity using the functional assessment of cancer therapy/gynecologic oncology group 12-item neurotoxicity questionnaire in a Phase II, multicenter, randomized, double-blind, placebo-controlled trial. <i>Journal of Cancer Research and Therapeutics</i> , 2021, 17, 1473. | 0.9 | 2 |
| 31 | Predicting factors for disappearance of anti-mutated citrullinated vimentin antibodies in sera of patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2020, 30, 450-457. | 1.8 | 3 |
| 32 | A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1-4, as a single dose and multiple doses in patients with solid malignancies. <i>Investigational New Drugs</i> , 2020, 38, 445-456. | 2.6 | 16 |
| 33 | Meta-analysis of two randomized phase III trials (TCOG GI-0801 and ECRIN TRICS) of biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer. <i>Gastric Cancer</i> , 2020, 23, 160-167. | 5.3 | 3 |
| 34 | A Randomized Controlled Trial of Telemedicine for Long-Term Sleep Apnea Continuous Positive Airway Pressure Management. <i>Annals of the American Thoracic Society</i> , 2020, 17, 329-337. | 3.2 | 31 |
| 35 | An adaptive power prior for sequential clinical trials Application to bridging studies. <i>Statistical Methods in Medical Research</i> , 2020, 29, 2282-2294. | 1.5 | 25 |
| 36 | Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study. <i>Breast Cancer</i> , 2020, 27, 389-398. | 2.9 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Prolonged air leak after reoperative pulmonary resection (with prior ipsilateral chest surgery). <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2020, 31, 544-546. | 1.1 | 1 |
| 38 | Disagreement between patient and physician reported outcomes on symptomatic adverse events as poor prognosis in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial. <i>Cancer Medicine</i> , 2020, 9, 9419-9430. | 2.8 | 5 |
| 39 | Prediction of pathological complete response after neoadjuvant chemotherapy in breast cancer by combining magnetic resonance imaging and core needle biopsy. <i>Surgical Oncology</i> , 2020, 35, 447-452. | 1.6 | 2 |
| 40 | Overnight fasting before lapatinib administration to breast cancer patients leads to reduced toxicity compared with nighttime dosing: a retrospective cohort study from a randomized clinical trial. <i>Cancer Medicine</i> , 2020, 9, 9246-9255. | 2.8 | 2 |
| 41 | Differences in disease status between patients with progression after first-line chemotherapy versus early relapse after adjuvant chemotherapy who undergo second-line chemotherapy for gastric cancer: Exploratory analysis of the randomized phase III TRICS trial. <i>European Journal of Cancer</i> , 2020, 132, 159-167. | 2.8 | 2 |
| 42 | Intake frequency of vegetables or seafoods negatively correlates with disease activity of rheumatoid arthritis. <i>PLoS ONE</i> , 2020, 15, e0228852. | 2.5 | 7 |
| 43 | Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01. <i>Breast Cancer</i> , 2020, 27, 631-641. | 2.9 | 6 |
| 44 | Proposed Definition for Oligometastatic Recurrence in Biliary Tract Cancer Based on Results of Locoregional Treatment: A Propensity-Score-Stratified Analysis. <i>Annals of Surgical Oncology</i> , 2020, 27, 1908-1917. | 1.5 | 7 |
| 45 | Patient-reported symptom burden as a prognostic factor in treatment with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial. <i>Cancer Medicine</i> , 2020, 9, 1779-1789. | 2.8 | 6 |
| 46 | Darbepoetin Alfa in Patients with Advanced CKD without Diabetes: Randomized, Controlled Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 608-615. | 4.5 | 10 |
| 47 | Predictive factors for structural remission using abatacept: Results from the ABROAD study. <i>Modern Rheumatology</i> , 2019, 29, 406-412. | 1.8 | 7 |
| 48 | Prevalence and factors associated with sarcopenia in patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2019, 29, 589-595. | 1.8 | 96 |
| 49 | Impact of pathological stage and histological subtype on clinical outcome of adjuvant chemotherapy of paclitaxel plus carboplatin versus oral uracil-tegafur for non-small cell lung cancer: subanalysis of SLCG0401 trial. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1367-1376. | 2.2 | 4 |
| 50 | Detection of atypical data in multicenter clinical trials using unsupervised statistical monitoring. <i>Clinical Trials</i> , 2019, 16, 512-522. | 1.6 | 13 |
| 51 | Risk-benefit point of the Model for End-stage Liver Disease score in patients waiting for deceased-donor liver transplantation: A single-center experience. <i>Hepatology Research</i> , 2019, 49, 687-694. | 3.4 | 3 |
| 52 | Anthracycline could be essential for triple-negative breast cancer: A randomised phase II study by the Kanagawa Breast Oncology Group (KBOG) 1101. <i>Breast</i> , 2019, 47, 1-9. | 2.2 | 13 |
| 53 | A Prospective, Randomized Phase II Study of Adjuvant Gemcitabine Versus S-1 After Major Hepatectomy for Biliary Tract Cancer (KHBO 1208). <i>Annals of Surgery</i> , 2019, 270, 230-237. | 4.2 | 41 |
| 54 | A study of second-line irinotecan plus cisplatin vs. irinotecan alone in platinum-naïve patients with early relapse of gastric cancer refractory to adjuvant S-1 monotherapy: exploratory subgroup analysis of the randomized phase III TRICS trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 867-874. | 2.3 | 4 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Induced pluripotent stem cell-based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients. <i>BMJ Open</i> , 2019, 9, e033131. | 1.9 | 32 |
| 56 | Comprehensive biomarker analyses identifies HER2, EGFR, MET RNA expression and thymidylate synthase 5'UTR SNP as predictors of benefit from S-1 adjuvant chemotherapy in Japanese patients with stage II/III gastric cancer. <i>Journal of Cancer</i> , 2019, 10, 5130-5138. | 2.5 | 1 |
| 57 | Gene expression profile of peripheral blood mononuclear cells may contribute to the identification and immunological classification of breast cancer patients. <i>Breast Cancer</i> , 2019, 26, 282-289. | 2.9 | 17 |
| 58 | Bayesian analysis of longitudinal dyadic data with informative missing data using a dyadic shared-parameter model. <i>Statistical Methods in Medical Research</i> , 2019, 28, 70-83. | 1.5 | 2 |
| 59 | EXPERT study: Randomized phase III trial of radical surgery and postoperative mFOLFOX6 versus perioperative mFOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases (CLMs).. <i>Journal of Clinical Oncology</i> , 2019, 37, 652-652. | 1.6 | 2 |
| 60 | Evaluation of efficacy of nivolumab by baseline factors from ATTRACTION-2.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8-8. | 1.6 | 3 |
| 61 | Impact of the prior chemotherapy with two different fluoropyrimidines on the efficacy of Capecitabine or FOLFIRI in metastatic colorectal cancer: An exploratory analysis of the phase III AXEPT trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 711-711. | 1.6 | 0 |
| 62 | A phase II trial of capecitabine plus cisplatin (XP) for patients with advanced gastric cancer with early relapse after S-1 adjuvant therapy: XParTS-I trial. <i>Gastric Cancer</i> , 2018, 21, 811-818. | 5.3 | 11 |
| 63 | Survival impact of post-progression chemotherapy in advanced gastric cancer: systematic review and meta-analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 981-989. | 2.3 | 29 |
| 64 | Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort. <i>Lung Cancer</i> , 2018, 117, 14-19. | 2.0 | 63 |
| 65 | Optimal dose selection accounting for patient subpopulations in a randomized Phase II trial to maximize the success probability of a subsequent Phase III trial. <i>Journal of Biopharmaceutical Statistics</i> , 2018, 28, 870-883. | 0.8 | 0 |
| 66 | Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 312 To colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 660-671. | 10.7 | 107 |
| 67 | Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study. <i>Breast Cancer</i> , 2018, 25, 108-117. | 2.9 | 4 |
| 68 | Planned Safety Analysis of the ACTS-CC 02 Trial: A Randomized Phase III Trial of S-1 With Oxaliplatin Versus Tegafur and Uracil With Leucovorin as Adjuvant Chemotherapy for High-Risk Stage III Colon Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, e153-e161. | 2.3 | 7 |
| 69 | Factors associated with prolonged time to treatment failure with fulvestrant 500mg in patients with post-menopausal estrogen receptor-positive advanced breast cancer: a sub-group analysis of the JBCRG-C06 Safari study. <i>Current Medical Research and Opinion</i> , 2018, 34, 49-54. | 1.9 | 8 |
| 70 | Comprehensive data of 3,820 patients newly diagnosed with colorectal liver metastasis between 2005 and 2007: report of a nationwide survey in Japan. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2018, 25, 115-123. | 2.6 | 17 |
| 71 | Placebo-Controlled, Double-Blinded Phase III Study Comparing Dexamethasone on Day 1 With Dexamethasone on Days 1 to 3 With Combined Neurokinin-1 Receptor Antagonist and Palonosetron in High-Emetogenic Chemotherapy. <i>Journal of Clinical Oncology</i> , 2018, 36, 1000-1006. | 1.6 | 55 |
| 72 | A prospective Phase II study to examine the relationship between quality of life and adverse events of first-line chemotherapy plus cetuximab in patients with KRAS wild-type unresectable metastatic colorectal cancer: QUACK trial. <i>Cancer Medicine</i> , 2018, 7, 4217-4227. | 2.8 | 12 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational Study. <i>Breast Cancer: Basic and Clinical Research</i> , 2018, 12, 117822341878624. | 1.1 | 2 |
| 74 | A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG07): therapeutic efficacy and clinical implications of circulating endothelial cells. <i>Cancer Medicine</i> , 2018, 7, 2442-2451. | 2.8 | 10 |
| 75 | The clinical impact of Hangeshashinto (TJ-14) in the treatment of chemotherapy-induced oral mucositis in gastric cancer and colorectal cancer: Analyses of pooled data from two phase II randomized clinical trials (HANGESHA-G and HANGESHA-C). <i>Journal of Cancer</i> , 2018, 9, 1725-1730. | 2.5 | 17 |
| 76 | A randomised phase II trial of capecitabine plus cisplatin versus S-1 plus cisplatin as a first-line treatment for advanced gastric cancer: Capecitabine plus cisplatin ascertainment versus S-1 plus cisplatin randomised PII trial (XParTS II). <i>European Journal of Cancer</i> , 2018, 101, 220-228. | 2.8 | 11 |
| 77 | Non-obese visceral adiposity is associated with the risk of atherosclerosis in Japanese patients with rheumatoid arthritis: a cross-sectional study. <i>Rheumatology International</i> , 2018, 38, 1679-1689. | 3.0 | 12 |
| 78 | Plasma concentrations of dasatinib have a clinical impact on the frequency of dasatinib dose reduction and interruption in chronic myeloid leukemia: an analysis of the DARIA 01 study. <i>International Journal of Clinical Oncology</i> , 2018, 23, 980-988. | 2.2 | 15 |
| 79 | ç”Ÿç% ©çµ±è~ã ã@ãŸçŽ. <i>Japanese Journal of Lung Cancer</i> , 2018, 58, 891-893. | 0.1 | 0 |
| 80 | Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer. <i>Breast Cancer</i> , 2017, 24, 111-120. | 2.9 | 21 |
| 81 | A simulation study of methods for selecting subgroup-specific doses in phase 1 trials. <i>Pharmaceutical Statistics</i> , 2017, 16, 143-156. | 1.3 | 10 |
| 82 | Bayesian Population Finding with Biomarkers in a Randomized Clinical Trial. <i>Biometrics</i> , 2017, 73, 1355-1365. | 1.4 | 16 |
| 83 | Carbamylated albumin is one of the target antigens of anti-carbamylated protein antibodies. <i>Rheumatology</i> , 2017, 56, 1217-1226. | 1.9 | 27 |
| 84 | Breathing-swallowing discoordination is associated with frequent exacerbations of COPD. <i>BMJ Open Respiratory Research</i> , 2017, 4, e000202. | 3.0 | 38 |
| 85 | S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study. <i>ESMO Open</i> , 2017, 2, e000135. | 4.5 | 17 |
| 86 | Cisplatin with dose-dense paclitaxel before and after radical hysterectomy for locally advanced cervical cancer: a prospective multicenter phase II trial with a dose-finding study. <i>Medical Oncology</i> , 2017, 34, 134. | 2.5 | 16 |
| 87 | Treatment Rationale and Design for J-AXEL: A Randomized Phase 3 Study Comparing Nab-Paclitaxel With Docetaxel in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 100-103. | 2.6 | 9 |
| 88 | Predictability of survival outcome by early tumor shrinkage (ETS) at 8 weeks with cutoff value of 20% in metastatic colorectal cancer (mCRC) patients treated with mFOLFOX6 plus bevacizumab (bev) or FOLFIRI plus bev as first-line chemotherapy (1st-CTx): Validation in the phase III WJOG4407G trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 729-729. | 1.6 | 1 |
| 89 | Meta-analysis of Patient-level Data on Therapeutic Effects of TJ-14 (Hangeshashinto) for Gastroenterological Cancer Chemotherapy-induced Severe Oral Mucositis with the HANGESHA-G and HANGESHA-Cs : protocol paper. <i>Annals of Cancer Research and Therapy</i> , 2017, 25, 92-94. | 0.3 | 0 |
| 90 | MEDICAL STATISTICS FOR SURGEONS. <i>Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical)</i> Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50 | | |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Study protocol of the Asian XELIRI Project (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab. <i>Chinese Journal of Cancer</i> , 2016, 35, 102. | 4.9 | 12 |
| 92 | Differences in Predictive Factors for Sustained Clinical Remission with Abatacept Between Younger and Elderly Patients with Biologic-naïve Rheumatoid Arthritis: Results from the ABROAD Study. <i>Journal of Rheumatology</i> , 2016, 43, 1974-1983. | 2.0 | 23 |
| 93 | Randomised phase III study of S-1 alone versus S-1 plus lentinan for unresectable or recurrent gastric cancer (JFMC36-0701). <i>European Journal of Cancer</i> , 2016, 65, 164-171. | 2.8 | 40 |
| 94 | A multicenter clinical study to determine the feasible initial dose of lenalidomide for maintenance therapy in patients with multiple myeloma following autologous peripheral blood stem-cell transplantation. <i>Molecular and Clinical Oncology</i> , 2016, 4, 965-970. | 1.0 | 0 |
| 95 | Bayesian adaptive patient enrollment restriction to identify a sensitive subpopulation using a continuous biomarker in a randomized phase 2 trial. <i>Pharmaceutical Statistics</i> , 2016, 15, 420-429. | 1.3 | 9 |
| 96 | Diagnostic criteria that can most accurately differentiate allergic bronchopulmonary mycosis from other eosinophilic lung diseases: A retrospective, single-center study. <i>Respiratory Investigation</i> , 2016, 54, 264-271. | 1.8 | 12 |
| 97 | A comparison of tacrolimus and cyclosporine combined with methotrexate for graft-versus-host disease prophylaxis, stratified by stem cell source: a retrospective nationwide survey. <i>International Journal of Hematology</i> , 2016, 103, 322-333. | 1.6 | 13 |
| 98 | Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic cancer receiving palliative chemotherapy. <i>International Journal of Clinical Oncology</i> , 2016, 21, 118-125. | 2.2 | 28 |
| 99 | Prognostic factors in patients with advanced thymic carcinoma treated with chemotherapy: A retrospective analysis of 289 patients from NEJ023 Study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8567-8567. | 1.6 | 1 |
| 100 | Impact of <i>UGT1A1</i> genotype on overall survival in Japanese advanced colorectal cancer patients treated by irinotecan-based regimens.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3571-3571. | 1.6 | 0 |
| 101 | Phase II study on radiofrequency ablation in early breast cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e12536-e12536. | 1.6 | 0 |
| 102 | Reply. <i>Annals of Thoracic Surgery</i> , 2015, 100, 1968-1969. | 1.3 | 0 |
| 103 | Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer. <i>BMC Cancer</i> , 2015, 15, 626. | 2.6 | 13 |
| 104 | Detecting Overall Survival Benefit Derived From Survival Postprogression Rather Than Progression-Free Survival. <i>Journal of the National Cancer Institute</i> , 2015, 107, . | 6.3 | 24 |
| 105 | Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients. <i>International Journal of Clinical Oncology</i> , 2015, 20, 709-722. | 2.2 | 7 |
| 106 | A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109). <i>Lung Cancer</i> , 2015, 87, 136-140. | 2.0 | 16 |
| 107 | Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer. <i>Gastric Cancer</i> , 2015, 18, 824-832. | 5.3 | 91 |
| 108 | Video-Assisted Thoracoscopic Lobectomy Versus Stereotactic Radiotherapy for Stage I Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2015, 99, 1122-1129. | 1.3 | 87 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial. <i>European Journal of Cancer</i> , 2015, 51, 808-816. | 2.8 | 40 |
| 110 | Factors associated with a poor response to gefitinib in the NEJ002 study: Smoking and the L858R mutation. <i>Lung Cancer</i> , 2015, 88, 181-186. | 2.0 | 29 |
| 111 | Incorporating Historical Data in Bayesian Phase I Trial Design: The Caucasian-to-Asian Toxicity Tolerability Problem. <i>Therapeutic Innovation and Regulatory Science</i> , 2015, 49, 93-99. | 1.6 | 6 |
| 112 | The utility of bi-weekly eribulin therapy for metastatic breast cancer: A Japanese multicenter phase II study (JUST-STUDY).. <i>Journal of Clinical Oncology</i> , 2015, 33, 1026-1026. | 1.6 | 1 |
| 113 | Impact of <i>UGT1A1</i> genotype on prognosis in Japanese advanced colorectal cancer patients treated by irinotecan-based regimens.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3525-3525. | 1.6 | 1 |
| 114 | A randomized phase II trial of capecitabine plus cisplatin (XP) versus S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment versus SP randomized PII trial (XParTS II).. <i>Journal of Clinical Oncology</i> , 2015, 33, 105-105. | 1.6 | 5 |
| 115 | The impact of early tumor shrinkage on survival in WJOG4407G trial, a randomized phase III trial of mFOLFOX6 plus bevacizumab versus FOLFIRI plus bevacizumab in first-line treatment for metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 679-679. | 1.6 | 2 |
| 116 | A randomized 2X2 phase II trial comparing two and four courses of S-1/cisplatin (SC) and paclitaxel/cisplatin (PC) as neoadjuvant chemotherapy for locally resectable advanced gastric cancer: Survival results of COMPASS.. <i>Journal of Clinical Oncology</i> , 2015, 33, 111-111. | 1.6 | 0 |
| 117 | Subset analysis of COMPASS: A randomized 2X2 phase II trial comparing two and four courses of S-1/cisplatin (SC) and paclitaxel/cisplatin (PC) as neoadjuvant chemotherapy for locally advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15067-e15067. | 1.6 | 0 |
| 118 | Exploring Ethnic Differences in Toxicity in Early-Phase Clinical Trials for Oncology Drugs. <i>Therapeutic Innovation and Regulatory Science</i> , 2014, 48, 644-650. | 1.6 | 4 |
| 119 | A Phase I/II Study of XELIRI Plus Bevacizumab as Second-Line Chemotherapy for Japanese Patients With Metastatic Colorectal Cancer (BIX Study). <i>Oncologist</i> , 2014, 19, 1131-1132. | 3.7 | 15 |
| 120 | Biomarker-based Bayesian randomized phase II clinical trial design to identify a sensitive patient subpopulation. <i>Statistics in Medicine</i> , 2014, 33, 4008-4016. | 1.6 | 12 |
| 121 | Comparison of long-term survival outcomes between stereotactic body radiotherapy and sublobar resection for stage I non-small-cell lung cancer in patients at high risk for lobectomy: A propensity score matching analysis. <i>European Journal of Cancer</i> , 2014, 50, 2932-2938. | 2.8 | 93 |
| 122 | CT analysis of the effect of pirfenidone in patients with idiopathic pulmonary fibrosis. <i>European Journal of Radiology</i> , 2014, 83, 32-38. | 2.6 | 65 |
| 123 | Updated results of the SOFT study: A randomized phase III trial of S-1/oxaliplatin (SOX) plus bevacizumab versus 5-FU/LV/oxaliplatin (mFOLFOX6) plus bevacizumab in patients with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 3586-3586. | 1.6 | 2 |
| 124 | Two phase III studies comparing 6 months of either mFOLFOX6 or XELOX with 3 months of the same regimen as adjuvant chemotherapy in patients with completely resected stage III colon cancer (ACHIEVE) or high-risk stage II colon cancer (ACHIEVE-2).. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS3655-TPS3655. | 1.6 | 1 |
| 125 | NEJ009 trial: A randomized phase III study of gefitinib (G) in combination with carboplatin (C) plus pemetrexed (P) versus G alone in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) with EGFR mutation.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS8131-TPS8131. | 1.6 | 6 |
| 126 | Harvesting lymph nodes in gastric cancer surgery: A prospective randomized controlled study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 28-28. | 1.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | Potential predictive markers of chemotherapy for advanced gastric cancer: Biomarker study in GC0301/TOP-002, randomized phase III study of irinotecan plus S-1 versus S-1.. Journal of Clinical Oncology, 2014, 32, 55-55. | 1.6 | 0 |
| 128 | Subgroup analyses of randomized phase II study on gemcitabine with an EPA-enriched oral supplement in advanced pancreatic cancer.. Journal of Clinical Oncology, 2014, 32, e20618-e20618. | 1.6 | 0 |
| 129 | An internally and externally validated nomogram to predict severe neutropenia in Japanese patients (pts) with advanced colorectal cancer (aCRC) treated with irinotecan (IRI)-based regimens.. Journal of Clinical Oncology, 2014, 32, 3543-3543. | 1.6 | 0 |
| 130 | First-line gemcitabine versus treatment of physician's choice in patients with metastatic and stage IV breast cancer: A prospective cohort study.. Journal of Clinical Oncology, 2014, 32, e12013-e12013. | 1.6 | 0 |
| 131 | The Pathological Response to Anthracycline is Associated with Topoisomerase II β Gene Amplification in the HER2 Breast Cancer Subset. Journal of Surgery and Science, 2014, 2, 10-12. | 0.0 | 1 |
| 132 | Phase II study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer. Anticancer Research, 2014, 34, 3583-8. | 1.1 | 2 |
| 133 | Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial. Journal of Clinical Oncology, 2013, 31, 4438-4444. | 1.6 | 439 |
| 134 | Double-Blind, Placebo-Controlled, Randomized Phase II Study of TJ-14 (Hangeshashinto) for Infusional Fluorinated-Pyrimidine-based Colorectal Cancer Chemotherapy-induced Oral Mucositis. Annals of Cancer Research and Therapy, 2013, 21, 26-30. | 0.3 | 1 |
| 135 | Prospective analysis of UGT1A1 genotyping for predicting toxicities in advanced colorectal cancer (aCRC) treated with irinotecan (IRI)-based regimens: Interim safety analysis of a Japanese observational study.. Journal of Clinical Oncology, 2013, 31, 3535-3535. | 1.6 | 1 |
| 136 | A comparison of postoperative quality of life after open and laparoscopic gastrectomy for early gastric cancer: A multicenter, nonrandomized, controlled study (CCOG 0802).. Journal of Clinical Oncology, 2013, 31, 4088-4088. | 1.6 | 1 |
| 137 | Multicenter, phase II study of trastuzumab and paclitaxel to treat HER2-positive, metastatic gastric cancer patients naive to trastuzumab (JFMC45-1102).. Journal of Clinical Oncology, 2013, 31, 4096-4096. | 1.6 | 3 |
| 138 | Safety of trastuzumab in HER2-positive primary breast cancer in Japan: Initial safety report for the large-scale cohort study (JBCRG C-01).. Journal of Clinical Oncology, 2013, 31, 613-613. | 1.6 | 1 |
| 139 | SAMIT: A phase III randomized clinical trial of adjuvant paclitaxel followed by oral fluorinated pyrimidines for locally advanced gastric cancer.. Journal of Clinical Oncology, 2013, 31, LBA4002-LBA4002. | 1.6 | 1 |
| 140 | Efficacy and safety of trastuzumab (T-mab) and paclitaxel for T-mab naïve patients with HER2 positive previously treated metastatic gastric cancer (JFMC45-1102).. Journal of Clinical Oncology, 2013, 31, 63-63. | 1.6 | 2 |
| 141 | Randomized phase II study of mixing steroid to reduce venous pain in patients with colorectal cancer receiving oxaliplatin through peripheral vein (APOLLO study).. Journal of Clinical Oncology, 2013, 31, 474-474. | 1.6 | 0 |
| 142 | A randomized phase II trial comparing docetaxel plus cyclophosphamide with epirubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy for hormone receptor-negative breast cancer: Kanagawa Breast Oncology Group (KBOG) 1101 study.. Journal of Clinical Oncology, 2013, 31, 1047-1047. | 1.6 | 1 |
| 143 | SAMIT: A phase III randomized clinical trial of adjuvant paclitaxel followed by oral fluorinated pyrimidines for locally advanced gastric cancer.. Journal of Clinical Oncology, 2013, 31, LBA4002-LBA4002. | 1.6 | 1 |
| 144 | Dynamic treatment regimen analysis to determine which treatment sequence can prolong survival of NSCLC patients.. Journal of Clinical Oncology, 2013, 31, e19010-e19010. | 1.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 145 | Phase II study of neoadjuvant chemotherapy with a metronomic regimen of paclitaxel + cyclophosphamide + capecitabine followed by 5-fluorouracil + epirubicin + cyclophosphamide in operable triple-negative breast cancer (JBCRG-13 study).. Journal of Clinical Oncology, 2013, 31, 1048-1048. | 1.6 | 0 |
| 146 | Evaluation of UGT1A1 genotyping for predicting individual toxicity of irinotecan plus platinum analog regimens: Interim safety analysis of a prospective observational study.. Journal of Clinical Oncology, 2013, 31, 11049-11049. | 1.6 | 0 |
| 147 | A prospective cohort study to reduce operative risk in stage I gastric cancer patients with metabolic syndrome: Preoperative exercise versus surgery alone.. Journal of Clinical Oncology, 2013, 31, e15112-e15112. | 1.6 | 0 |
| 148 | Early results of a randomized phase II, compass trial to compare regimen and duration of neoadjuvant chemotherapy for gastric cancer.. Journal of Clinical Oncology, 2013, 31, 4102-4102. | 1.6 | 0 |
| 149 | Prior Effective Sample Size in Conditionally Independent Hierarchical Models. Bayesian Analysis, 2012, 7, . | 3.0 | 30 |
| 150 | A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II). BMC Cancer, 2012, 12, 307. | 2.6 | 12 |
| 151 | Combination chemotherapy with S-1 plus cisplatin for gastric cancer that recurs after adjuvant chemotherapy with S-1: multi-institutional retrospective analysis. Gastric Cancer, 2012, 15, 245-251. | 5.3 | 19 |
| 152 | Randomized phase III study of irinotecan (CPT-11) versus weekly paclitaxel (wPTX) for advanced gastric cancer (AGC) refractory to combination chemotherapy (CT) of fluoropyrimidine plus platinum (FP): WJOG4007 trial.. Journal of Clinical Oncology, 2012, 30, 4002-4002. | 1.6 | 17 |
| 153 | Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR).. Journal of Clinical Oncology, 2012, 30, 7521-7521. | 1.6 | 71 |
| 154 | A multidisciplinary treatment comprising standard chemotherapy with vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for Ewing sarcoma family of tumor (ESFT) in Japan: Results of the first Japan Ewing Sarcoma Study (JESS) 04.. Journal of Clinical Oncology, 2012, 30, 9574-9574. | 1.6 | 0 |
| 155 | What factors affect long-term survival after responding to gefitinib in advanced non-small cell lung cancer? Real-world evidence.. Journal of Clinical Oncology, 2012, 30, e18007-e18007. | 1.6 | 0 |
| 156 | Application of the continual reassessment method to a phase I dose-finding trial in Japanese patients: East meets West. Statistics in Medicine, 2011, 30, 2090-2097. | 1.6 | 18 |
| 157 | Evaluating the Impact of Prior Assumptions in Bayesian Biostatistics. Statistics in Biosciences, 2010, 2, 1-17. | 1.2 | 29 |
| 158 | A Bayesian Hierarchical Mixture Model for Platelet-Derived Growth Factor Receptor Phosphorylation to Improve Estimation of Progression-Free Survival in Prostate Cancer. Journal of the Royal Statistical Society Series C: Applied Statistics, 2010, 59, 19-34. | 1.0 | 6 |
| 159 | A Human Epidermal Growth Factor Receptor 2 Expression-based Approach to Neoadjuvant Chemotherapy for Operable Breast Cancer. Japanese Journal of Clinical Oncology, 2010, 40, 620-626. | 1.3 | 4 |
| 160 | Phase III Trial Comparing Oral S-1 Plus Carboplatin With Paclitaxel Plus Carboplatin in Chemotherapy-Naïve Patients With Advanced Non-Small-Cell Lung Cancer: Results of a West Japan Oncology Group Study. Journal of Clinical Oncology, 2010, 28, 5240-5246. | 1.6 | 161 |
| 161 | Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR. New England Journal of Medicine, 2010, 362, 2380-2388. | 27.0 | 5,032 |
| 162 | Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncology, The, 2010, 11, 121-128. | 10.7 | 3,794 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 163 | Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS) Tj ETQq1 1 0.7843 14 rg55/Overl | 1.4 | 182 |
| 164 | A Decision Analysis of Unrelated Hematopoietic Stem Cell Transplantation for Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia In First Remission Who Lack An HLA-Matched Sibling. Blood, 2010, 116, 3527-3527. | 1.4 | 1 |
| 165 | Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non-EGFR Mutations. Clinical Cancer Research, 2009, 15, 4493-4498. | 7.0 | 182 |
| 166 | Determining the Effective Sample Size of a Parametric Prior. Biometrics, 2008, 64, 595-602. | 1.4 | 188 |